Ambey Laboratories (AMBEY) 주식 개요앰베이 래버러토리스 리미티드는 인도에서 농약, 화합물 및 관련 의약품을 제조 및 판매하는 회사입니다. 자세히 보기AMBEY 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성3/6배당0/6강점주가수익률(13.8x)이 Indian 시장(23.2x)보다 낮습니다.위험 분석이자 지급액이 수익으로 잘 충당되지 않음지난 5년간 매년 수익이 13.1% 감소했습니다.지난 3개월 동안 주가 변동성이 Indian 시장과 비교했을 때 매우 높았습니다.높은 수준의 비현금 수입+ 위험 1건 추가모든 위험 점검 보기AMBEY Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹24.6094.3% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01b2016201920222025202620282031Revenue ₹1.3bEarnings ₹44.4mAdvancedSet Fair ValueView all narrativesAmbey Laboratories Limited 경쟁사Teesta Agro IndustriesSymbol: BSE:524204Market cap: ₹680.1mCrop Life ScienceSymbol: NSEI:CLSLMarket cap: ₹711.3mAristo Bio-Tech and LifescienceSymbol: NSEI:ARISTOMarket cap: ₹827.8mAgro Phos (India)Symbol: NSEI:AGROPHOSMarket cap: ₹610.7m가격 이력 및 성과Ambey Laboratories 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹24.6052주 최고가₹48.3052주 최저가₹16.20베타01개월 변동-29.91%3개월 변동-12.14%1년 변동-42.79%3년 변동n/a5년 변동n/aIPO 이후 변동-72.44%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).분석 기사 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).분석 기사 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m).New Risk • Nov 24New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m).분석 기사 • Nov 15There Is A Reason Ambey Laboratories Limited's (NSE:AMBEY) Price Is UndemandingWith a price-to-earnings (or "P/E") ratio of 22.6x Ambey Laboratories Limited ( NSE:AMBEY ) may be sending bullish...공시 • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.공시 • Sep 04Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year.분석 기사 • Jul 19Ambey Laboratories Limited's (NSE:AMBEY) Business And Shares Still Trailing The MarketAmbey Laboratories Limited's ( NSE:AMBEY ) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy...New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m).Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m).New Risk • May 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m).Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India.Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).New Risk • Sep 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m).공시 • Sep 13Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time.New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m).Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India.Buy Or Sell Opportunity • Jul 23Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%.공시 • Jul 11Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 330,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,868,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,252,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 936,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,184,000 Price\Range: INR 68 Transaction Features: Regulation S; Rule 144ABoard Change • Jul 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.주주 수익률AMBEYIN ChemicalsIN 시장7D-13.7%0.1%-0.2%1Y-42.8%-2.7%0.02%전체 주주 수익률 보기수익률 대 산업: AMBEY은 지난 1년 동안 -2.7%의 수익을 기록한 Indian Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: AMBEY은 지난 1년 동안 0%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is AMBEY's price volatile compared to industry and market?AMBEY volatilityAMBEY Average Weekly Movement12.7%Chemicals Industry Average Movement7.2%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%안정적인 주가: AMBEY의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: AMBEY의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트1985n/aArchit Guptaambeylab.com앰베이 래버러토리스 리미티드는 인도에서 농약, 화합물 및 관련 의약품을 제조 및 판매하는 회사입니다. 이 회사는 아민염, 나트륨염, 헥사코나졸뿐만 아니라 산 기술, 에틸 에스테르 기술, 에틸헥실 에스테르 기술 제품을 제공합니다. 또한 제품을 수출하고 있습니다.더 보기Ambey Laboratories Limited 기초 지표 요약Ambey Laboratories의 순이익과 매출은 시가총액과 어떻게 비교됩니까?AMBEY 기초 통계시가총액₹643.63m순이익 (TTM)₹44.37m매출 (TTM)₹1.33b13.8x주가수익비율(P/E)0.5x주가매출비율(P/S)AMBEY는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표AMBEY 손익계산서 (TTM)매출₹1.33b매출원가₹1.17b총이익₹153.83m기타 비용₹109.46m순이익₹44.37m최근 보고된 실적Sep 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)1.78총이익률11.59%순이익률3.34%부채/자본 비율43.8%AMBEY의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 11:30종가2026/05/22 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ambey Laboratories Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).
분석 기사 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).
분석 기사 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m).
New Risk • Nov 24New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m).
분석 기사 • Nov 15There Is A Reason Ambey Laboratories Limited's (NSE:AMBEY) Price Is UndemandingWith a price-to-earnings (or "P/E") ratio of 22.6x Ambey Laboratories Limited ( NSE:AMBEY ) may be sending bullish...
공시 • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025
Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
공시 • Sep 04Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year.
분석 기사 • Jul 19Ambey Laboratories Limited's (NSE:AMBEY) Business And Shares Still Trailing The MarketAmbey Laboratories Limited's ( NSE:AMBEY ) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy...
New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m).
Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m).
New Risk • May 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m).
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India.
Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).
New Risk • Sep 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m).
공시 • Sep 13Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time.
New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m).
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Buy Or Sell Opportunity • Jul 23Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%.
공시 • Jul 11Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 330,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,868,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,252,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 936,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,184,000 Price\Range: INR 68 Transaction Features: Regulation S; Rule 144A
Board Change • Jul 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
